Lack of clinically significant drug interactions between nevirapine and buprenorphine.
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceNew developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsImportant Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine ProductsUsefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
P2860
Q27692040-F298D097-34A6-4A43-9F58-00CF805BD7A8Q34952233-3B57F68A-9BA4-48F9-80BC-902C9C1212BFQ35184385-72BD9B05-1CC4-42FF-A246-005AEDA53984Q35228546-D5B44A7C-E3CC-4DB6-93B2-CF194B869758Q35672530-1FE204D5-9EF9-446F-8166-53BCF1F25194Q35738851-3B2DDDF1-B816-4A9A-9D72-C65828BAB7C9Q37570243-48FF2867-AEC7-4261-BA81-172E8ED9494DQ37721776-3382F15C-2E3A-4530-904C-E4B770E84D6CQ37763615-443686BD-297A-4F9C-910D-DD85846F3DD9Q37962449-969B7381-E540-4A59-9EE4-61A73741D8A0Q38435908-1C6DE636-6905-4935-AA99-7136B1F9E348Q38513275-CDF46868-3DA9-409C-A415-04D73998C37AQ48296522-AE11893C-1E8C-4DC7-88D3-89FC2421C2CD
P2860
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@en
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@nl
type
label
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@en
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@nl
prefLabel
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@en
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@nl
P2093
P2860
P1476
Lack of clinically significant drug interactions between nevirapine and buprenorphine.
@en
P2093
David E Moody
Elinore F McCance-Katz
Gene D Morse
Petrie M Rainey
P2860
P356
10.1111/J.1521-0391.2009.00006.X
P577
2010-01-01T00:00:00Z